Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01771107 · OUTCOME

Maximal Tolerated Dose of Brentuximab Vedotin (Phase I)

Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With Stage II-IV HIV-Associated Hodgkin Lymphoma · Source last updated 2025-08-15

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
mg/kg
Interval / dispersion
Not reported
Time frame
28 days

What was measured

Defined as the dose level at which =\< 1 of 6 subjects experience dose limiting toxicity.

Analysis population: Participants entered into the phase I portion of the study

Groups in this outcome

Treatment (Brentuximab and Combination Chemotherapy)

Patients receive doxorubicin hydrochloride IV, vinblastine sulfate IV, and dacarbazine IV on days 1 and 15. Patients also receive brentuximab vedotin IV over 30 minutes on days 1 and 15. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Brentuximab Vedotin: Given IV Dacarbazine: Given IV Doxorubicin Hydrochloride: Given IV Pharmacological Study: Correlative studies Vinblastine: Given IV

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Treatment (Brentuximab and Combination Chemotherapy)6

Reported measurements

Source class 1
Values in mg/kg · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Treatment (Brentuximab and Combination Chemotherapy)1.2Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        1.2
denoms
  1. counts
    1. group Id
      OG000
      value
      6
    units
    Participants
description
Defined as the dose level at which =\< 1 of 6 subjects experience dose limiting toxicity.
groups
  1. description
    Patients receive doxorubicin hydrochloride IV, vinblastine sulfate IV, and dacarbazine IV on days 1 and 15. Patients also receive brentuximab vedotin IV over 30 minutes on days 1 and 15. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Brentuximab Vedotin: Given IV Dacarbazine: Given IV Doxorubicin Hydrochloride: Given IV Pharmacological Study: Correlative studies Vinblastine: Given IV
    id
    OG000
    title
    Treatment (Brentuximab and Combination Chemotherapy)
param Type
NUMBER
population Description
Participants entered into the phase I portion of the study
reporting Status
POSTED
time Frame
28 days
title
Maximal Tolerated Dose of Brentuximab Vedotin (Phase I)
type
PRIMARY
unit Of Measure
mg/kg

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice